How to Help Your Patients Save Money on Glycopyrronium: A Provider's Guide to Savings Programs

The cost of glycopyrronium varies dramatically by formulation. While generic glycopyrrolate tablets cost as little as $13/month with a discount card, specialty products like Qbrexza and COPD inhalers can cost hundreds to over $500 per month at list price. As a prescriber, understanding the savings landscape for each formulation empowers you to reduce financial barriers for your patients and improve medication adherence.

Cost Overview by Formulation

Generic glycopyrrolate tablets (1 mg, 2 mg): Retail $60–$95 per 60 tablets; as low as $12–$13 with GoodRx or SingleCare. Insurance typically Tier 1-2, copay $0–$30. Low cost barrier.

Qbrexza (topical cloth, 2.4%): List price approximately $500–$600+/month. With Almirall savings card: as low as $0/month (commercially insured). GoodRx: ~$62. High cost barrier without intervention.

Cuvposa (pediatric oral solution): Retail ~$452+/month. With GoodRx: ~$62. Medicaid typically covers for qualifying pediatric patients. Compounding available at $30–$80/month.

COPD inhalers (Seebri Neohaler, Lonhala Magnair, Bevespi Aerosphere): List price $300–$600+/month. Manufacturer savings programs may reduce to $0–$25/month for eligible commercially insured patients. Medicare Part D covers with copay varying by plan tier.

Qbrexza: Almirall Savings Program and Prior Authorization

For dermatologists prescribing Qbrexza, the savings landscape is favorable for commercially insured patients if you act at the time of prescribing:

Almirall Commercial Savings Card: Eligible commercially insured patients can pay as little as $0 per month for Qbrexza. The patient or your staff can enroll online or via the manufacturer's dedicated access team. This program is not available for government-insured patients (Medicare, Medicaid).

Prior Authorization Documentation: Most commercial plans require PA for Qbrexza. Standard documentation includes: diagnosis of primary axillary hyperhidrosis, severity assessment (HDSS score or equivalent), and prior treatment failure with aluminum chloride topicals. Submitting at the time of visit prevents delays.

Bridge prescriptions: While PA is pending (typically 2–5 business days), prescribe Drysol (aluminum chloride 20%) as a bridge. This also satisfies prior treatment failure documentation for many plans.

Medicare and Medicaid patients: The Almirall copay card cannot be used for government-insured patients. These patients may qualify for a Medicaid exception or manufacturer patient assistance. Contact Almirall patient services for income-based assistance options.

Cuvposa: Insurance Coverage and Alternatives

For pediatric neurologists and pediatricians prescribing Cuvposa for sialorrhea:

Medicaid coverage: Most state Medicaid programs cover Cuvposa for qualifying pediatric patients with neurological conditions. Confirm formulary status with your state Medicaid program; PA may be required.

GoodRx coupon: GoodRx reduces Cuvposa from ~$452 to approximately $62 for patients paying cash. Provide GoodRx information at the time of prescribing for uninsured or underinsured patients.

Compounding as a cost-effective alternative: Compounded glycopyrrolate oral suspension costs $30–$80/month at many compounding pharmacies — a fraction of Cuvposa's retail price. Document acceptability in the chart so your staff can authorize it without calling you each time.

COPD Inhalers Containing Glycopyrronium: Savings Programs

For pulmonologists and PCPs prescribing glycopyrronium-containing COPD inhalers:

Seebri Neohaler (Sunovion): Sunovion offers patient support programs. Commercially insured patients may pay as little as $0–$25/month with the savings card. Contact Sunovion patient services or visit the brand website.

Lonhala Magnair (Theravance Biopharma): Patient savings programs available for commercially insured patients. Uninsured and underinsured patients should inquire about patient assistance.

Bevespi Aerosphere (AstraZeneca): AstraZeneca AZ&Me patient assistance program provides medications at no cost to uninsured patients who meet income criteria. Commercial savings cards available for insured patients.

Formulary optimization: Before prescribing a specific glycopyrronium inhaler, check the patient's formulary. Tiotropium (Spiriva) is often on a preferred tier and may have a lower copay with equivalent efficacy. Choosing the formulary-preferred LAMA at initiation eliminates a common access barrier.

Generic Glycopyrrolate: Streamlining Access for Patients

For the large population of patients on generic glycopyrrolate tablets (ulcer adjunct, off-label hyperhidrosis):

Always prescribe as "generic glycopyrrolate" — not a brand name — to ensure the lowest cost and maximum substitution flexibility.

Advise patients to compare prices using GoodRx or SingleCare before filling — prices vary by pharmacy and can differ by $10–$30 for the same drug.

Recommend 90-day supplies via mail-order for patients on stable chronic therapy — lower per-pill cost and reduced trips to the pharmacy.

Handling PA Denials and Appeals

Prior authorization denials for specialty glycopyrronium products (Qbrexza, COPD inhalers) are common but frequently overturned on appeal. Best practices:

Document severity (HDSS score ≥3 for hyperhidrosis; FEV1 grade for COPD) explicitly in the PA submission.

List prior treatment failures clearly — insurance plans often require step therapy through cheaper alternatives before approving specialty agents.

For urgent situations, request a peer-to-peer review — direct physician-to-physician discussions with the plan's medical director have higher approval rates than written appeals.

Directing Patients to medfinder for Pharmacy Location

Once cost is addressed, patients still need to find a pharmacy that has their formulation in stock. medfinder calls pharmacies near the patient to check for their specific prescription and texts results to them — saving patient and staff time. For practices with high volumes of glycopyrronium prescriptions, directing patients to medfinder at the point of prescribing can reduce inbound "where do I find this?" calls significantly.

Summary Table: Savings Programs by Formulation

Generic tablets: GoodRx (~$13), SingleCare (~$12), prescribe generic (not brand)

Qbrexza: Almirall savings card ($0/month commercially insured), GoodRx (~$62), Almirall PAP (uninsured)

Cuvposa: Medicaid coverage, GoodRx (~$62), compounding (~$30–$80/month)

COPD inhalers: Manufacturer copay cards ($0–$25/month commercially insured), AZ&Me PAP (AstraZeneca), formulary-preferred LAMA substitution

For the patient-facing version of this information, see our guide on how to save money on glycopyrronium.